OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-01-01 to 2025-01-01.)

Article	Citations
A landscape analysis and discussion of value of gene therapies for sickle cell disease	48
Adherence to augmentation therapy for the treatment of major depressive disorder	38
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment	26
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	23
The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature	20
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening	20
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain	18
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care	17
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review	16
The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study	15
The implications of cardiac device cybersecurity responsibilities and challenges faced by policymakers, manufacturers, and patients	15
Social care data in the UK; current landscape, challenges, and future recommendations	14
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial	13
Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia	13
Economic evaluation of stereotactic radiotherapy and stereotactic radiosurgery technologies in the treatment of cancers: a systematic review	12
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data	12
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system	11
The cost-of-illness of multiple sclerosis in Jordan	11
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study	11
Effects of utilization management on health outcomes: evidence from urinary tract infections and community-acquired pneumonia	10
Addressing racial/ethnic disparities associated with Medicare Part D Star Ratings among population with Alzheimer’s disease and related dementias	10
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	10
Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review	10
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe	9
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment	9

Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	9
How to create value with constrained budgets in oncological care? A narrative review	9
Cost-effectiveness of hysterectomy, first- and second-generation endometrial ablation, and levonorgestrel-releasing device for treatment of heavy menstrual bleeding: a systematic review	9
Incorporating public and wider stakeholder views in the design of health state valuation studies in adults and young people: an undervalued resource?	9
The hidden burden of atopic dermatitis in central and Eastern European countries	9
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	8
Challenges and opportunities in measuring the pediatric quality of life: exemplified by research in pediatric gastroenterology	8
Real-world analysis of cost, treatment patterns, and outcomes of patients with metastatic cutaneous squamous cell carcinoma in the US	8
Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database	8
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States	8
Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review	8
Hospital care of endometriosis in Spain: a retrospective multicenter analysis of patient characteristics and costs	7
Evaluating the correlations of cost and utility parameters from summary statistics for probabilistic analysis in economic evaluations	7
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia	7
A latanoprost cationic emulsion (STN1013001) vs. other latanoprost formulations (Latanoprost) in open angle glaucoma/ocular hypertension and ocular surface disease: an Italian cost-utility analysis	7
A comparison of six approaches for measuring utility values among patients with locally advanced cervical cancer	7
Disparities in Respiratory Syncytial Virus Risk Factors, Diagnosis, and Outcomes in Adults by Race, Ethnicity, and Other Social Determinants of Health in the United States	7
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	7
Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study	7
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain	7
Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review	7
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?	6
Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer	6
Content and cost of waste pharmaceuticals collected by pharmacies for disposal	6
Early economic evaluation of an intervention to improve uptake of the NHS England Diabetes Prevention Programme	6
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	6
Not cost-effective at zero price: valuing and paying for combination therapies in cancer	6
Analysis of patients’ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece	6
Economic evaluation of interventions to improve medication adherence among patients with chronic diseases: an overview of systematic reviews	6
Interview with Julie Frappier, health economist, and creator of the TOWWERS™ System	6
Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency	5
Nonadherence to antiseizure medications: what have we learned and what can be done next?	5
Assessing the economic impact of digital endpoints on medication adherence	5
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study	5
Economic benefits of global Collaborative Health technology	5
Overview and quality assessment of health economic evaluations for homeopathic therapy: an updated systematic review	5
A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden	5
Natural language processing – relevance to patient outcomes and real-world evidence	5
What to expect in 2024: important health economics and outcomes research (HEOR) trends	5
Analysis of prescriptive monitoring regarding the current therapeutic landscape of rheumatoid arthritis: the experience of an Italian local health authority	5
Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US	4
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs	4
The long-term clinical impact of digital endpoints and biomarkers in data collection	4
Risk prediction algorithms in guiding antiviral therapy initiation among patients with chronic hepatitis B in Thailand: an economic evaluation and budget impact analysis	4
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China	4
Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications	4
Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension	4
Distinguishing features in the assessment of mHealth apps	4
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain	4
Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument	4

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS II) statement: a validated Dutch translation	4
Description of characteristics, management of care and healthcare direct costs of patients with HR+/HER2- early breast cancer in Italy: a real-world study involving administrative and pathological ana	4
Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?	4
The utility and impact of digital endpoints for improving breast cancer outcomes	4
Coping with increasing medicine costs through greater adoption of generic prescribing and dispensing in Pakistan as an exemplar country	4
Can we achieve affordable cancer medicine prices? Developing a pathway for change	4
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data	4
The role of insurance policies in the drug pricing landscape	4
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment	4
Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer	4
Burden of illness the first year after diagnosed bladder dysfunction among people with spinal cord injury or multiple sclerosis – a Danish register study	4
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer	4
Cost-effectiveness of dapagliflozin plus standard treatment compared to standard therapy for the management of chronic kidney disease in Colombia	4
Canadian English translation and linguistic validation of the 13-MD to measure global health-related quality of life	4
Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia	4
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study	4
An early cost analysis of magnetic bone growth stimulation in England	3
Measuring valued output in primary care: challenges and reconciliation	3
Assessment of women’s treatment preferences for vasomotor symptoms due to menopause	3
Economic burden of depression in Brazil: a cost-of-illness study based on productivity losses and healthcare costs between 2010 to 2018	3
What might have happened: the impact of interrupting entry of innovative drugs on disease outcomes in the United States	3
Budgetary impact analysis of alteplase - recombinant tissue plasminogen activator (rtPA) - as a thrombolytic treatment for acute ischemic stroke in Colombia	3
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	3
Health-related quality of life measured using the EQ-5D-3L: iranian population norms	3
An early health technology assessment of 3D anatomic models in pediatric congenital heart surgery: potential cost-effectiveness and decision uncertainty	3
The cost-effectiveness of using rapid diagnostic tests for the diagnosis of typhoid fever in patients with suspected typhoid fever: a systematic review	3
Value-based performance arrangements for chronic conditions: an economic simulation of Medicaid Drug Rebate Program reforms	3
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective	3
Artificial intelligence in outcomes research: a systematic scoping review	3
A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury	3
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis	3
Burden of disease and costs of infections associated with cardiac implantable electronic devices	3
The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach	3
Consumption of antidepressants and economic austerity in Brazil	3
Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study	3
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	3
A visual approach to the economic evaluation of vaccines: opening the health economic black box	3
Comparing measurement properties of EQ-5D and SF-6D in East and South-East Asian populations: a scoping review	3
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A	3
The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma	3
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer	3
Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil	3
Evaluation instruments for executive functions in children and adolescents: a systematic review	3
Canadian French translation and linguistic validation of the health-related quality of life utility measure for pre-school children	3
Prescription drug coverage satisfaction and medication nonadherence among Medicare beneficiaries with cancer	3
Cost-effectiveness analyses comparing cemented, cementless, hybrid and reverse hybrid fixation in total hip arthroplasty: a systematic overview and critical appraisal of the current evidence	3